
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc. has an enterprise value of approximately $430 million, providing a potential for significant upside in its stock value, especially if its partnership with Novopro proves to be successful. The company's management anticipates improved efficiency in executing Phase 1 trials for its products, particularly with SEP-786, driven by prior experience. Additionally, the promising performance of SEP-631, which has the potential to mirror the success of Xolair—an anti-IgE monoclonal antibody with nearly $3.9 billion in sales in 2023—coupled with preclinical data indicating enhanced dosing convenience and a longer half-life for candidates, reinforces a positive outlook for Septerna's future growth and development.
Bears say
Septerna Inc faces several risks that contribute to a negative outlook on its stock, including potential delays in clinical development for key candidates like SEP-631 and other pipeline products. Setbacks in clinical trials and partnership uncertainties, particularly with Novo Nordisk, could hinder the company’s progress and impact its market position. Additionally, concerns over achieving market penetration and the possibility of long-term dilution further exacerbate the financial outlook, as highlighted by a recent transaction in the obesity sector that suggests a valuation gap for Septerna.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares